Recombinant Human Type VIII Collagen for Solubility and Processability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Collagens derived from animal tissues exhibit poor water solubility and weak processability, limiting their applications in various studies and products.
Innovation Solution
Development of recombinant human type VIII collagen using genetic engineering technology, specifically through the use of specific amino acid sequences (SEQ ID NO: 1, 4, 7, 10, 13, 16, 19, 22, 25, 28) or variants, which are linked directly or via a linker, and suitable for expression and purification in E. coli, with potential applications in biological dressings, human bionic materials, and plastic surgery materials.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If collagen is derived from animal tissues, then it can be obtained through traditional extraction methods, but it exhibits poor water solubility and weak processability
Solution Approach 1:
The patent creates a recombinant human type VIII collagen that copies the natural collagen structure and function but produces it through genetic engineering in E. coli bacteria rather than extracting from animal tissues. This synthetic copy maintains the beneficial properties of natural collagen while eliminating the solubility and processability issues associated with animal-derived collagens
Solution Approach 2:
The patent modifies the collagen production parameters by changing the source from animal tissues to recombinant bacterial expression. By optimizing the expression system, purification conditions, and structural characteristics of the recombinant collagen, the patent achieves improved water solubility and processability while maintaining the functional integrity of the collagen molecule
2Productivity
If recombinant human type VIII collagen is produced in E. coli, then expression levels and purification effects are improved, but the complexity of genetic engineering and expression system setup increases
Solution Approach 1:
The patent divides the collagen production process into distinct functional modules: a promoter region for gene expression control, a coding sequence for type VIII collagen, a signal peptide for secretion, and a terminator sequence. This segmentation allows each element to be independently optimized and facilitates the assembly of the expression construct, reducing overall complexity
Solution Approach 2:
The patent develops a universal expression system that can be applied to produce different collagen types and variants using the same basic plasmid backbone and transformation protocol in E. coli. This multi-functional platform reduces the need for developing separate complex systems for each collagen product, thereby improving productivity while managing complexity
Data Source
AI summary
Provided is a method for biosynthesis of a human body structural material type-VIII collagen. Also provided is a collagen, comprising one or more repeating units, wherein the repeating units are connected directly or by means of linkers, and each repeating unit comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 1, 4, 7, 10, 13, 16, 19, 22, 25 or 28, or a variant thereof. The collagen can be used for biological dressings, human body bionic materials or plastic surgery materials. According to the method, the type-VIII collagen is produced by utilizing a genetic engineering technology, thereby overcoming the defects in the prior art.